Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

China Pharma Holdings (CPHI) Enterprise Value (2016 - 2025)

China Pharma Holdings (CPHI) has disclosed Enterprise Value for 16 consecutive years, with -$267625.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Enterprise Value rose 62.76% year-over-year to -$267625.0, compared with a TTM value of -$267625.0 through Sep 2025, up 62.76%, and an annual FY2024 reading of -$626879.0, up 55.97% over the prior year.
  • Enterprise Value was -$267625.0 for Q3 2025 at China Pharma Holdings, up from -$625032.0 in the prior quarter.
  • Across five years, Enterprise Value topped out at -$267625.0 in Q3 2025 and bottomed at -$4.9 million in Q4 2021.
  • Average Enterprise Value over 5 years is -$1.4 million, with a median of -$901910.0 recorded in 2023.
  • The sharpest move saw Enterprise Value crashed 594.97% in 2022, then soared 68.59% in 2023.
  • Year by year, Enterprise Value stood at -$4.9 million in 2021, then surged by 58.22% to -$2.0 million in 2022, then grew by 29.86% to -$1.4 million in 2023, then surged by 55.97% to -$626879.0 in 2024, then soared by 57.31% to -$267625.0 in 2025.
  • Business Quant data shows Enterprise Value for CPHI at -$267625.0 in Q3 2025, -$625032.0 in Q2 2025, and -$412688.0 in Q1 2025.